Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : IPIC -- Ignore unavailable to you. Want to Upgrade?

To: KS who wrote (1322)	7/16/1999 11:00:00 AM
From: Bill Hanna	Read Replies (2) \| Respond to of 1359

This one looks like a winner. Lots of good things coming and with investor interest continuing today after the heavy volume yesterday. Short term, do you think it will move up to 6.25 ?

To: KS who wrote (1322)	8/5/1999 10:41:00 PM
From: Cacaito	Read Replies (2) \| Respond to of 1359

IPIC gives back 4.2 M shares (some $20 M per Intercardia actual market share) in exchange for increase rights in Bextra (and in the entity so called CPEC LLC). Ipic does not have more interest in the rest of Intercardia (now Incara?)science. Not even a week later, Bextra is proven worthless. Well they are looking for more data. Bextra (bucindolol)used to look promising since many other beta blockers has shown benefit, but the fact is Bextra did not. Bextra apparent advantage is the minimal vasodilation effects, now it is proven with not effects at all. Now Knoll gives their rights back, so no more expenses for Knoll in the Bextra failure. IPIC is now hanging on Citicoline. Pagoclone is still far behind. The Leptin/AMGN works is never mentioned, Do they have still anything left on the Leptin business? The cash is their only value, and is decreasing steadily each quarter. From $72M to $37M Debt of $27M, real equity about $10M. This is something like $0.25 per share. Minus the $80 M ? liability in cash or stock from the Redux debacle. The founder and holder of important patents is given a farewell. Will IPIC comeback? Citicoline is the only hope and with its drawbacks at the FDA is better to wait for the end of trial.